185 related articles for article (PubMed ID: 32324887)
1. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.
Short NJ; Patel KP; Albitar M; Franquiz M; Luthra R; Kanagal-Shamanna R; Wang F; Assi R; Montalban-Bravo G; Matthews J; Ma W; Loghavi S; Takahashi K; Issa GC; Kornblau SM; Jabbour E; Garcia-Manero G; Kantarjian HM; Estrov Z; Ravandi F
Blood Adv; 2020 Apr; 4(8):1670-1677. PubMed ID: 32324887
[TBL] [Abstract][Full Text] [Related]
2. Targeted Next-Generation Sequencing of Circulating Tumor DNA, Bone Marrow, and Peripheral Blood Mononuclear Cells in Pediatric AML.
Ruan M; Liu L; Qi B; Chen X; Chang L; Zhang A; Liu F; Wang S; Liu X; Chen X; Zhang L; Guo Y; Zou Y; Zhang Y; Chen Y; Liu L; Cao S; Lou F; Wang C; Zhu X
Front Oncol; 2021; 11():666470. PubMed ID: 34422630
[TBL] [Abstract][Full Text] [Related]
3. Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer.
Vietsch EE; Graham GT; McCutcheon JN; Javaid A; Giaccone G; Marshall JL; Wellstein A
Cancer Genet; 2017 Dec; 218-219():39-50. PubMed ID: 29153095
[TBL] [Abstract][Full Text] [Related]
4. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
[TBL] [Abstract][Full Text] [Related]
5. Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.
Delsing Malmberg E; Rehammar A; Pereira MB; Abrahamsson J; Samuelsson T; Ståhlman S; Asp J; Tierens A; Palmqvist L; Kristiansson E; Fogelstrand L
J Mol Diagn; 2019 Jan; 21(1):149-162. PubMed ID: 30273780
[TBL] [Abstract][Full Text] [Related]
6. Measurable residual disease monitoring for patients with acute myeloid leukemia following hematopoietic cell transplantation using error corrected hybrid capture next generation sequencing.
Balagopal V; Hantel A; Kadri S; Steinhardt G; Zhen CJ; Kang W; Wanjari P; Ritterhouse LL; Stock W; Segal JP
PLoS One; 2019; 14(10):e0224097. PubMed ID: 31658273
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse.
Kim T; Moon JH; Ahn JS; Kim YK; Lee SS; Ahn SY; Jung SH; Yang DH; Lee JJ; Choi SH; Lee JY; Tyndel MS; Shin MG; Lee YJ; Sohn SK; Park SK; Zhang Z; Kim HJ; Kim DDH
Blood; 2018 Oct; 132(15):1604-1613. PubMed ID: 30108064
[TBL] [Abstract][Full Text] [Related]
8. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
9. Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.
Kim JJ; Jang JE; Lee HA; Park MR; Kook HW; Lee ST; Choi JR; Min YH; Shin S; Cheong JW
Ann Lab Med; 2023 Jul; 43(4):328-336. PubMed ID: 36843401
[TBL] [Abstract][Full Text] [Related]
10. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
[TBL] [Abstract][Full Text] [Related]
11. Molecular Minimal Residual Disease in Acute Myeloid Leukemia.
Jongen-Lavrencic M; Grob T; Hanekamp D; Kavelaars FG; Al Hinai A; Zeilemaker A; Erpelinck-Verschueren CAJ; Gradowska PL; Meijer R; Cloos J; Biemond BJ; Graux C; van Marwijk Kooy M; Manz MG; Pabst T; Passweg JR; Havelange V; Ossenkoppele GJ; Sanders MA; Schuurhuis GJ; Löwenberg B; Valk PJM
N Engl J Med; 2018 Mar; 378(13):1189-1199. PubMed ID: 29601269
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.
Luthra R; Patel KP; Reddy NG; Haghshenas V; Routbort MJ; Harmon MA; Barkoh BA; Kanagal-Shamanna R; Ravandi F; Cortes JE; Kantarjian HM; Medeiros LJ; Singh RR
Haematologica; 2014 Mar; 99(3):465-73. PubMed ID: 24142997
[TBL] [Abstract][Full Text] [Related]
13. Analysis of colorectal cancer-related mutations by liquid biopsy: Utility of circulating cell-free DNA and circulating tumor cells.
Takeda K; Yamada T; Takahashi G; Iwai T; Ueda K; Kuriyama S; Koizumi M; Matsuda A; Shinji S; Ohta R; Yokoyama Y; Hotta M; Hara K; Yoshida H
Cancer Sci; 2019 Nov; 110(11):3497-3509. PubMed ID: 31465598
[TBL] [Abstract][Full Text] [Related]
14. Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence.
Pasternack H; Fassunke J; Plum PS; Chon SH; Hescheler DA; Gassa A; Merkelbach-Bruse S; Bruns CJ; Perner S; Hallek M; Büttner R; Bollschweiler E; Hölscher AH; Quaas A; Zander T; Weiss J; Alakus H
Sci Rep; 2018 Oct; 8(1):14941. PubMed ID: 30297788
[TBL] [Abstract][Full Text] [Related]
15. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Morita K; Kantarjian HM; Wang F; Yan Y; Bueso-Ramos C; Sasaki K; Issa GC; Wang S; Jorgensen J; Song X; Zhang J; Tippen S; Thornton R; Coyle M; Little L; Gumbs C; Pemmaraju N; Daver N; DiNardo CD; Konopleva M; Andreeff M; Ravandi F; Cortes JE; Kadia T; Jabbour E; Garcia-Manero G; Patel KP; Futreal PA; Takahashi K
J Clin Oncol; 2018 Jun; 36(18):1788-1797. PubMed ID: 29702001
[TBL] [Abstract][Full Text] [Related]
16. A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.
Onecha E; Linares M; Rapado I; Ruiz-Heredia Y; Martinez-Sanchez P; Cedena T; Pratcorona M; Oteyza JP; Herrera P; Barragan E; Montesinos P; Vela JAG; Magro E; Anguita E; Figuera A; Riaza R; Martinez-Barranco P; Sanchez-Vega B; Nomdedeu J; Gallardo M; Martinez-Lopez J; Ayala R
Haematologica; 2019 Feb; 104(2):288-296. PubMed ID: 30093399
[TBL] [Abstract][Full Text] [Related]
17. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
18. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
19. The minimal that kills: Why defining and targeting measurable residual disease is the "Sine Qua Non" for further progress in management of acute myeloid leukemia.
Bewersdorf JP; Shallis RM; Boddu PC; Wood B; Radich J; Halene S; Zeidan AM
Blood Rev; 2020 Sep; 43():100650. PubMed ID: 31883804
[TBL] [Abstract][Full Text] [Related]
20. Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia.
Yang F; Anekpuritanang T; Press RD
Mol Diagn Ther; 2020 Feb; 24(1):1-13. PubMed ID: 31848884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
